All In Biotech

Drug Trial Radar · NCT04562389

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 353 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

353

Actual

Start

Mar 11, 2021

Primary completion

Feb 20, 2026

Study completion Mar 2028

Sponsor

Lead sponsor
Karyopharm Therapeutics IncIndustry
Sponsor type
Industry
First posted
Sep 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b). Phase 3 (ongoing), double-blind, placebo-controlled part of the study comparing the efficacy and safety of combination therapy of selinexor + ruxolitinib with combination of placebo + ruxolitinib.

Conditions

  • Myelofibrosis

Interventions

  • SelinexorDrug

    Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.

  • SelinexorDrug

    Participants will receive a dose of 60 mg selinexor oral tablets QW.

  • PlaceboOther

    Participants will receive a matching placebo of selinexor oral tablets QW

  • RuxolitinibDrug

    Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 3: Proportion of Participants with Spleen Volume Reduction (SVR) of Greater than or Equal to (>=) 35 Percent (%) (SVR35) at Week 24 Measured by the Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) ScanTime frame: At Week 24
  2. Phase 3: Absolute mean change in TSS (Abs-TSS) from baseline to Week 24 as measured by the Myelofibrosis Symptom Assessment Form (MFSAF) v4.0Time frame: At Week 24
  3. Phase 1: Maximum Tolerated Dose (MTD)Time frame: Approximately within the first cycle (28 days) of therapy
  4. Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: Approximately within the first cycle (28 days) of therapy
  5. Phase 1: Number of Participants With Adverse Events (AEs) by Occurrence, Nature, and SeverityTime frame: From start of drug administration up to 30 days after last dose of study treatment (approximately 48 months)

Locations

166 sites in 20 countries. Site status is shown where the registry gives one.

  • UAB Division of Hematology/Oncology

    Birmingham, Alabama

  • UCLA - Satellite Site

    Beverly Hills, California

  • City of Hope

    Duarte, California

  • UCLA - Satellite Site

    Encino, California

  • City of Hope - Irvine Lennar - Satellite

    Irvine, California

  • UCLA

    Los Angles, California

  • The Oncology Institute of Hope & Innovation

    Pasadena, California

  • USOR - Rocky Mountain Cancer Centers - Aurora

    Aurora, Colorado

  • Smilow Cancer Hospital - New Haven

    New Haven, Connecticut

  • Georgetown Lombardi Comprehensive Center

    Washington D.C., District of Columbia

  • Norton Cancer Institute - Saint Matthews

    Louisville, Kentucky

  • Maryland Oncology Hematology-Satellite

    Annapolis, Maryland

  • The Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Maryland Oncology Hematology-Satellite

    Brandywine, Maryland

  • Maryland Oncology Hematology

    Columbia, Maryland

  • Maryland Oncology Hematology-Satellite

    Rockville, Maryland

  • Maryland Oncology Hematology-Satellite

    Silver Spring, Maryland

  • The Cancer & Hematology Centers -Satellite Site

    Grand Rapids, Michigan

  • The Cancer & Hematology Centers of Muskegon

    Norton Shores, Michigan

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Mount Sinai Health System

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke Cancer Institue

    Durham, North Carolina

  • USOR - Oncology Hematology Care - Kenwood

    Cincinnati, Ohio

  • Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute

    Columbus, Ohio

  • OhioHealth

    Columbus, Ohio

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • Texas Oncology

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • USOR - Virginia Cancer Specialists - Gainesville Office

    Gainesville, Virginia

  • VCU Massey Cancer Center

    Richmond, Virginia

  • USOR - Virginia Oncology Associates - Virginia Beach

    Virginia Beach, Virginia

  • Fred Hutchinson Cancer Center - SCAA South Lake Union

    Seattle, Washington

  • West Virginia University Cancer Institute, Wheeling Hospital

    Wheeling, West Virginia

  • University of Wisconsin - Madison

    Madison, Wisconsin

  • Bankstown-Lidcombe Hospital

    Bankstown, New South Wales, Australia

  • Campbelltown Hospital

    Campbelltown, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Icon Cancer Centre - Wesley

    South Brisbane, Queensland, Australia

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.